> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves EyePoint Pharma Uveitis Drug
- URL: https://www.fdaweb.com/fda-approves-eyepoint-pharma-uveitis-drug/
- Published: 2018-10-15T12:00:00.000Z
- Updated: 2026-09-15T00:38:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142587

FDA has approved EyePoint Pharmaceuticals’ Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior segment of the eye. The product uses the company’s Durasert drug delivery technology and is a non-bioerodible intravitreal micro-insert in a drug delivery system containing 0.18 mg fluocinolone acetonide, designed to release consistently over 36 months. It is supplied in a sterile single-dose preloaded applicator that can be administered in the physician's office. In clinical trials, the drug significantly reduced the rate of recurrent uveitis flares versus sham, and the most common adverse reactions reported were cataract development and increase in intraocular pressure.